Richard B Slansky
CIK 1224981 · Chief Financial Officer · last filed 2026-04-01
Richard B Slansky is a Chief Financial Officer who has filed 34 SEC Form 4 insider transactions across 4 companies since 2009. The most recent filing, for GNTA, was dated Apr 1, 2026. Across all open-market trades the lifetime net is +$866.1K, making them a net buyer over the disclosed history. 15 SEC filings were submitted jointly with STAR EQUITY HOLDINGS, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ONCS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GNTA | Chief Financial Officer | — | $0.98 | — | $0 | 1 | 2026-04-01 |
| ONCOSEC MEDICAL Inc (ONCS) Delisted | Chief Financial Officer | 1,269 | $0.28 | $352 | $799.5K | 8 | 2018-07-06 |
| GenMark Diagnostics, Inc. (GNMK) Delisted | Chief Financial Officer | 111,836 | $24.04 | $2.69M | $66.5K | 10 | 2014-03-13 |
| STAR EQUITY HOLDINGS, INC. (DRAD) Delisted | Chief Financial Officer | 2,904 | — | — | $0 | 14 | 2012-04-12 |
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-01 | GNTA | Grant (A) | — | $0 | EDGAR |
| 2018-07-06 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Mixed | +115,016 | -$118.5K | EDGAR |
| 2018-05-07 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-17 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-03-31 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-16 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Mixed | — | $0 | EDGAR |
| 2016-03-08 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-08-24 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-07-08 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Buy (P) | +150,000 | $918.0K | EDGAR |
| 2014-03-13 | GenMark Diagnostics, Inc. (GNMK) Delisted | Sell (S) | −1,680 | -$20.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.